Lung Cancer
Volume 75, Issue 2 , Pages 146-150, February 2012

Implementation of hypoxia measurement into lung cancer therapy

  • Xue Meng

      Affiliations

    • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
  • ,
  • Feng-Ming (Spring) Kong

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, USA
  • ,
  • Jinming Yu

      Affiliations

    • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China
    • Corresponding Author InformationCorresponding author at: No 440, Jiyan Road, Shandong 250117, China. Tel.: +86 531 87984729; fax: +86 531 87984079.

Received 1 July 2011; received in revised form 11 September 2011; accepted 14 September 2011. published online 17 October 2011.

Abstract 

Tumor hypoxia has been found to be a characteristic feature in lung cancer. It has been shown to decrease the therapeutic efficacy of radiotherapy and some forms of chemotherapy. New methods for qualitative and quantitative assessment of tumor oxygenation have made it possible to establish the prognostic significance of tumor hypoxia. The ability to determine the degree and extent of hypoxia in lung cancer is not only important prognostically, but also in the selection of patients for hypoxia-modifying treatments. To provide the best attainable quality of life for individual patients it is of increasing importance that tools be developed that allow a better selection of patients for these intensified treatment strategies. Although some markers and combinations have shown potential benefit and are associated with treatment outcome, their clinical usefulness needs to be validated in prospective trials. A review of published studies was carried out, focusing on the assessment of tumor hypoxia and the possibilities to overcome hypoxia during treatment in lung cancer.

Keywords: Hypoxia, Lung cancer, FETNIM, FMISO, FAZA, PET imaging

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(11)00478-8

doi:10.1016/j.lungcan.2011.09.009

Lung Cancer
Volume 75, Issue 2 , Pages 146-150, February 2012